Analysts expect Innophos Holdings, Inc. (NASDAQ:IPHS) to report $0.60 EPS on May, 7.They anticipate $0.01 EPS change or 1.69% from last quarter’s $0.59 EPS. IPHS’s profit would be $11.73 million giving it 17.45 P/E if the $0.60 EPS is correct. After having $0.52 EPS previously, Innophos Holdings, Inc.’s analysts see 15.38% EPS growth. The stock increased 0.94% or $0.39 during the last trading session, reaching $41.88. About 28,872 shares traded. Innophos Holdings, Inc. (NASDAQ:IPHS) has declined 27.20% since April 17, 2017 and is downtrending. It has underperformed by 38.75% the S&P500.
Sphera Funds Management Ltd decreased Orbotech Ltd (ORBK) stake by 75.18% reported in 2017Q4 SEC filing. Sphera Funds Management Ltd sold 131,755 shares as Orbotech Ltd (ORBK)’s stock rose 23.02%. The Sphera Funds Management Ltd holds 43,488 shares with $2.19M value, down from 175,243 last quarter. Orbotech Ltd now has $2.95B valuation. The stock decreased 0.07% or $0.04 during the last trading session, reaching $60.8. About 380,964 shares traded. Orbotech Ltd. (NASDAQ:ORBK) has risen 91.25% since April 17, 2017 and is uptrending. It has outperformed by 79.70% the S&P500.
Innophos Holdings, Inc., through its subsidiaries, produces performance-critical and nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care, and industrial end markets. The company has market cap of $818.41 million. It operates through Food, Health & Nutrition, Industrial Specialties, and Other divisions. It has a 37.06 P/E ratio. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture additives in cheeses; leavening agents in baked goods; mineral and botanical sources for nutritional supplements; pharmaceutical excipients; and abrasives in toothpaste, as well as in industrial applications, such as asphalt modification and petrochemical catalysis.
Investors sentiment decreased to 1.1 in Q4 2017. Its down 0.26, from 1.36 in 2017Q3. It dropped, as 28 investors sold Innophos Holdings, Inc. shares while 54 reduced holdings. 40 funds opened positions while 50 raised stakes. 18.14 million shares or 1.26% less from 18.37 million shares in 2017Q3 were reported. Bailard owns 0.05% invested in Innophos Holdings, Inc. (NASDAQ:IPHS) for 16,700 shares. Price T Rowe Inc Md stated it has 11,134 shares. Panagora Asset Mgmt invested in 196,095 shares. Axa holds 0.01% of its portfolio in Innophos Holdings, Inc. (NASDAQ:IPHS) for 70,300 shares. Gemmer Asset Mgmt Limited Co reported 99 shares or 0% of all its holdings. Brown Advisory has 0% invested in Innophos Holdings, Inc. (NASDAQ:IPHS). Ny State Teachers Retirement reported 0% stake. Teacher Retirement Of Texas reported 6,754 shares. Employees Retirement Association Of Colorado owns 5,997 shares. Moreover, Thomson Horstmann Bryant Inc has 0.12% invested in Innophos Holdings, Inc. (NASDAQ:IPHS). Ls Inv Advisors Limited Company stated it has 0% in Innophos Holdings, Inc. (NASDAQ:IPHS). Alpha Windward Ltd Limited Liability Company owns 11,760 shares or 0.33% of their US portfolio. Financial Bank Of Montreal Can holds 831 shares or 0% of its portfolio. Los Angeles Cap And Equity accumulated 32,290 shares. Robeco Institutional Asset Mngmt Bv reported 12,435 shares.
Among 3 analysts covering Innophos Holdings (NASDAQ:IPHS), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Innophos Holdings had 7 analyst reports since August 24, 2015 according to SRatingsIntel. The company was maintained on Tuesday, October 31 by KeyBanc Capital Markets. On Thursday, October 20 the stock rating was initiated by Sidoti with “Buy”. The firm has “Buy” rating by Sidoti given on Friday, May 26. As per Thursday, September 3, the company rating was downgraded by Zacks. Zacks upgraded the stock to “Sell” rating in Monday, August 24 report. The firm has “Hold” rating by KeyBanc Capital Markets given on Wednesday, September 6. The rating was downgraded by Sidoti to “Neutral” on Friday, December 16.
Among 10 analysts covering Orbotech (NASDAQ:ORBK), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. Orbotech had 27 analyst reports since September 8, 2015 according to SRatingsIntel. The firm has “Outperform” rating by RBC Capital Markets given on Friday, November 6. The rating was initiated by Cowen & Co with “Outperform” on Tuesday, January 5. The rating was maintained by Needham with “Buy” on Monday, November 16. The rating was maintained by Lake Street on Monday, January 22 with “Buy”. The rating was downgraded by Jefferies on Tuesday, March 20 to “Hold”. The firm has “Buy” rating by Oppenheimer given on Thursday, February 15. The firm has “Buy” rating by Lake Street given on Tuesday, September 8. On Monday, February 12 the stock rating was maintained by Jefferies with “Buy”. Jefferies maintained Orbotech Ltd. (NASDAQ:ORBK) on Monday, September 11 with “Buy” rating. Lake Street downgraded the shares of ORBK in report on Tuesday, March 20 to “Hold” rating.
Sphera Funds Management Ltd increased Minerva Neurosciences Inc (NASDAQ:NERV) stake by 150,000 shares to 775,000 valued at $4.69 million in 2017Q4. It also upped Prothena Corp Plc (NASDAQ:PRTA) stake by 145,000 shares and now owns 205,000 shares. Clearside Biomedical Inc was raised too.
Analysts await Orbotech Ltd. (NASDAQ:ORBK) to report earnings on May, 2. They expect $0.71 earnings per share, up 69.05% or $0.29 from last year’s $0.42 per share. ORBK’s profit will be $34.40M for 21.41 P/E if the $0.71 EPS becomes a reality. After $0.82 actual earnings per share reported by Orbotech Ltd. for the previous quarter, Wall Street now forecasts -13.41% negative EPS growth.